nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—CYP3A7—Sorafenib—liver cancer	0.0793	0.124	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0793	0.124	CbGbCtD
Lidocaine—CYP2B6—Sorafenib—liver cancer	0.0756	0.118	CbGbCtD
Lidocaine—CYP3A5—Sorafenib—liver cancer	0.0595	0.0931	CbGbCtD
Lidocaine—CYP2C8—Sorafenib—liver cancer	0.0572	0.0895	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—liver cancer	0.0458	0.0717	CbGbCtD
Lidocaine—CYP1A2—Sorafenib—liver cancer	0.0443	0.0693	CbGbCtD
Lidocaine—CYP2C9—Sorafenib—liver cancer	0.0399	0.0624	CbGbCtD
Lidocaine—ABCB1—Sorafenib—liver cancer	0.0387	0.0606	CbGbCtD
Lidocaine—CYP2D6—Sorafenib—liver cancer	0.0365	0.0571	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—liver cancer	0.0235	0.0368	CbGbCtD
Lidocaine—CYP3A4—Sorafenib—liver cancer	0.0232	0.0363	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—liver cancer	0.0221	0.0346	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—liver cancer	0.0141	0.022	CbGbCtD
Lidocaine—Hoarseness—Sorafenib—liver cancer	0.00469	0.0426	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Sorafenib—liver cancer	0.00284	0.0258	CcSEcCtD
Lidocaine—Dysphonia—Sorafenib—liver cancer	0.00251	0.0228	CcSEcCtD
Lidocaine—Skin exfoliation—Sorafenib—liver cancer	0.00197	0.0179	CcSEcCtD
Lidocaine—Neurotoxicity—Epirubicin—liver cancer	0.00197	0.0179	CcSEcCtD
Lidocaine—Neuropathy—Sorafenib—liver cancer	0.00194	0.0176	CcSEcCtD
Lidocaine—Neurotoxicity—Doxorubicin—liver cancer	0.00182	0.0165	CcSEcCtD
Lidocaine—Leukoderma—Epirubicin—liver cancer	0.00179	0.0163	CcSEcCtD
Lidocaine—Leukoderma—Doxorubicin—liver cancer	0.00166	0.0151	CcSEcCtD
Lidocaine—Local reaction—Epirubicin—liver cancer	0.00138	0.0125	CcSEcCtD
Lidocaine—Dysphagia—Sorafenib—liver cancer	0.00129	0.0118	CcSEcCtD
Lidocaine—Local reaction—Doxorubicin—liver cancer	0.00127	0.0116	CcSEcCtD
Lidocaine—Neuropathy peripheral—Sorafenib—liver cancer	0.00113	0.0103	CcSEcCtD
Lidocaine—Redness—Epirubicin—liver cancer	0.00113	0.0103	CcSEcCtD
Lidocaine—Stomatitis—Sorafenib—liver cancer	0.00113	0.0102	CcSEcCtD
Lidocaine—Paralysis—Epirubicin—liver cancer	0.0011	0.00997	CcSEcCtD
Lidocaine—Burning sensation—Epirubicin—liver cancer	0.0011	0.00997	CcSEcCtD
Lidocaine—Blister—Epirubicin—liver cancer	0.00106	0.00961	CcSEcCtD
Lidocaine—Redness—Doxorubicin—liver cancer	0.00105	0.0095	CcSEcCtD
Lidocaine—Haemoglobin—Sorafenib—liver cancer	0.00104	0.00946	CcSEcCtD
Lidocaine—Haemorrhage—Sorafenib—liver cancer	0.00104	0.00941	CcSEcCtD
Lidocaine—Paralysis—Doxorubicin—liver cancer	0.00102	0.00923	CcSEcCtD
Lidocaine—Burning sensation—Doxorubicin—liver cancer	0.00102	0.00923	CcSEcCtD
Lidocaine—Blister—Doxorubicin—liver cancer	0.000979	0.00889	CcSEcCtD
Lidocaine—Hyperaesthesia—Epirubicin—liver cancer	0.000972	0.00883	CcSEcCtD
Lidocaine—Feeling hot—Epirubicin—liver cancer	0.000972	0.00883	CcSEcCtD
Lidocaine—Gingivitis—Epirubicin—liver cancer	0.000972	0.00883	CcSEcCtD
Lidocaine—Tinnitus—Sorafenib—liver cancer	0.000966	0.00878	CcSEcCtD
Lidocaine—Flushing—Sorafenib—liver cancer	0.000962	0.00874	CcSEcCtD
Lidocaine—Cardiac disorder—Sorafenib—liver cancer	0.000962	0.00874	CcSEcCtD
Lidocaine—Angiopathy—Sorafenib—liver cancer	0.00094	0.00854	CcSEcCtD
Lidocaine—Immune system disorder—Sorafenib—liver cancer	0.000936	0.0085	CcSEcCtD
Lidocaine—Petechiae—Epirubicin—liver cancer	0.000927	0.00842	CcSEcCtD
Lidocaine—Dysphonia—Epirubicin—liver cancer	0.000927	0.00842	CcSEcCtD
Lidocaine—Erythema—Sorafenib—liver cancer	0.000902	0.0082	CcSEcCtD
Lidocaine—Feeling hot—Doxorubicin—liver cancer	0.000899	0.00817	CcSEcCtD
Lidocaine—Gingivitis—Doxorubicin—liver cancer	0.000899	0.00817	CcSEcCtD
Lidocaine—Hyperaesthesia—Doxorubicin—liver cancer	0.000899	0.00817	CcSEcCtD
Lidocaine—Dysgeusia—Sorafenib—liver cancer	0.000884	0.00803	CcSEcCtD
Lidocaine—Petechiae—Doxorubicin—liver cancer	0.000858	0.00779	CcSEcCtD
Lidocaine—Dysphonia—Doxorubicin—liver cancer	0.000858	0.00779	CcSEcCtD
Lidocaine—Angioedema—Sorafenib—liver cancer	0.000824	0.00749	CcSEcCtD
Lidocaine—Dysarthria—Epirubicin—liver cancer	0.000806	0.00733	CcSEcCtD
Lidocaine—Loss of consciousness—Sorafenib—liver cancer	0.000793	0.0072	CcSEcCtD
Lidocaine—Atrioventricular block—Epirubicin—liver cancer	0.000786	0.00714	CcSEcCtD
Lidocaine—Hypertension—Sorafenib—liver cancer	0.000779	0.00708	CcSEcCtD
Lidocaine—Ventricular tachycardia—Epirubicin—liver cancer	0.000763	0.00693	CcSEcCtD
Lidocaine—Dermatitis contact—Epirubicin—liver cancer	0.000754	0.00685	CcSEcCtD
Lidocaine—Dysarthria—Doxorubicin—liver cancer	0.000746	0.00678	CcSEcCtD
Lidocaine—Anaphylactic shock—Sorafenib—liver cancer	0.000736	0.00669	CcSEcCtD
Lidocaine—Skin exfoliation—Epirubicin—liver cancer	0.000728	0.00661	CcSEcCtD
Lidocaine—Atrioventricular block—Doxorubicin—liver cancer	0.000728	0.00661	CcSEcCtD
Lidocaine—Shock—Sorafenib—liver cancer	0.000724	0.00658	CcSEcCtD
Lidocaine—Nervous system disorder—Sorafenib—liver cancer	0.000722	0.00656	CcSEcCtD
Lidocaine—Neuropathy—Epirubicin—liver cancer	0.000716	0.00651	CcSEcCtD
Lidocaine—Ventricular tachycardia—Doxorubicin—liver cancer	0.000706	0.00641	CcSEcCtD
Lidocaine—Dermatitis contact—Doxorubicin—liver cancer	0.000697	0.00634	CcSEcCtD
Lidocaine—Coma—Epirubicin—liver cancer	0.000697	0.00633	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—liver cancer	0.000674	0.00612	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—liver cancer	0.000663	0.00602	CcSEcCtD
Lidocaine—Dyspnoea—Sorafenib—liver cancer	0.000656	0.00596	CcSEcCtD
Lidocaine—Coma—Doxorubicin—liver cancer	0.000645	0.00586	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Sorafenib—liver cancer	0.000636	0.00577	CcSEcCtD
Lidocaine—Pain—Sorafenib—liver cancer	0.00063	0.00572	CcSEcCtD
Lidocaine—Urticaria—Sorafenib—liver cancer	0.000585	0.00531	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—liver cancer	0.000579	0.00526	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—liver cancer	0.000572	0.0052	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—liver cancer	0.000554	0.00503	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—liver cancer	0.000554	0.00503	CcSEcCtD
Lidocaine—Hypersensitivity—Sorafenib—liver cancer	0.000542	0.00493	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—liver cancer	0.000536	0.00487	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000529	0.00481	CcSEcCtD
Lidocaine—Asthenia—Sorafenib—liver cancer	0.000528	0.0048	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—liver cancer	0.000526	0.00478	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—liver cancer	0.000512	0.00465	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—liver cancer	0.000512	0.00465	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—liver cancer	0.000487	0.00443	CcSEcCtD
Lidocaine—Dizziness—Sorafenib—liver cancer	0.000487	0.00442	CcSEcCtD
Lidocaine—Asthma—Epirubicin—liver cancer	0.000479	0.00435	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—liver cancer	0.000479	0.00435	CcSEcCtD
Lidocaine—Vomiting—Sorafenib—liver cancer	0.000468	0.00425	CcSEcCtD
Lidocaine—Rash—Sorafenib—liver cancer	0.000464	0.00422	CcSEcCtD
Lidocaine—Dermatitis—Sorafenib—liver cancer	0.000464	0.00421	CcSEcCtD
Lidocaine—Headache—Sorafenib—liver cancer	0.000461	0.00419	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—liver cancer	0.000443	0.00402	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—liver cancer	0.000443	0.00402	CcSEcCtD
Lidocaine—Nausea—Sorafenib—liver cancer	0.000437	0.00397	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—liver cancer	0.000427	0.00388	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—liver cancer	0.000418	0.0038	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—liver cancer	0.000416	0.00378	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—liver cancer	0.000395	0.00359	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—liver cancer	0.00039	0.00354	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—liver cancer	0.000387	0.00352	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—liver cancer	0.000385	0.0035	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—liver cancer	0.000385	0.0035	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—liver cancer	0.000384	0.00349	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—liver cancer	0.000383	0.00348	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—liver cancer	0.000381	0.00346	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—liver cancer	0.000369	0.00335	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—liver cancer	0.000361	0.00328	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—liver cancer	0.000358	0.00325	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—liver cancer	0.000357	0.00324	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—liver cancer	0.000356	0.00324	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—liver cancer	0.000355	0.00323	CcSEcCtD
Lidocaine—Flushing—Epirubicin—liver cancer	0.000355	0.00323	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—liver cancer	0.000355	0.00323	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—liver cancer	0.000354	0.00322	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—liver cancer	0.000353	0.0032	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—liver cancer	0.000348	0.00316	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—liver cancer	0.000346	0.00314	CcSEcCtD
Lidocaine—Chills—Epirubicin—liver cancer	0.000344	0.00312	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—liver cancer	0.000342	0.0031	CcSEcCtD
Lidocaine—Erythema—Epirubicin—liver cancer	0.000333	0.00303	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—liver cancer	0.000331	0.00301	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—liver cancer	0.00033	0.003	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—liver cancer	0.000329	0.00299	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—liver cancer	0.000329	0.00299	CcSEcCtD
Lidocaine—Tension—Epirubicin—liver cancer	0.000327	0.00297	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—liver cancer	0.000327	0.00297	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—liver cancer	0.000324	0.00294	CcSEcCtD
Lidocaine—Back pain—Epirubicin—liver cancer	0.000323	0.00293	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—liver cancer	0.000322	0.00292	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—liver cancer	0.00032	0.00291	CcSEcCtD
Lidocaine—Chills—Doxorubicin—liver cancer	0.000318	0.00289	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—liver cancer	0.000314	0.00285	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—liver cancer	0.000309	0.0028	CcSEcCtD
Lidocaine—Agitation—Epirubicin—liver cancer	0.000306	0.00278	CcSEcCtD
Lidocaine—Tension—Doxorubicin—liver cancer	0.000303	0.00275	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—liver cancer	0.000302	0.00274	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—liver cancer	0.0003	0.00272	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—liver cancer	0.000298	0.00271	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—liver cancer	0.000293	0.00266	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—liver cancer	0.000291	0.00264	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—liver cancer	0.000289	0.00262	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—liver cancer	0.000288	0.00261	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—liver cancer	0.000284	0.00258	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—liver cancer	0.000284	0.00258	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—liver cancer	0.000283	0.00257	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—liver cancer	0.000274	0.00249	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—liver cancer	0.000272	0.00247	CcSEcCtD
Lidocaine—Oedema—Epirubicin—liver cancer	0.000272	0.00247	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—liver cancer	0.000271	0.00246	CcSEcCtD
Lidocaine—Shock—Epirubicin—liver cancer	0.000268	0.00243	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—liver cancer	0.000267	0.00243	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—liver cancer	0.000267	0.00242	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—liver cancer	0.000266	0.00242	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—liver cancer	0.000263	0.00239	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—liver cancer	0.000263	0.00239	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—liver cancer	0.000262	0.00238	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—liver cancer	0.000254	0.00231	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—liver cancer	0.000254	0.00231	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—liver cancer	0.000252	0.00229	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—liver cancer	0.000252	0.00229	CcSEcCtD
Lidocaine—Shock—Doxorubicin—liver cancer	0.000248	0.00225	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—liver cancer	0.000247	0.00224	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—liver cancer	0.000244	0.00222	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—liver cancer	0.000243	0.00221	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—liver cancer	0.000243	0.0022	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—liver cancer	0.000242	0.0022	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—liver cancer	0.000235	0.00214	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—liver cancer	0.000235	0.00213	CcSEcCtD
Lidocaine—Pain—Epirubicin—liver cancer	0.000233	0.00211	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—liver cancer	0.000226	0.00205	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—liver cancer	0.000224	0.00204	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—liver cancer	0.000224	0.00204	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—liver cancer	0.000224	0.00203	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000217	0.00197	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—liver cancer	0.000216	0.00196	CcSEcCtD
Lidocaine—Pain—Doxorubicin—liver cancer	0.000215	0.00196	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—liver cancer	0.000207	0.00188	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—liver cancer	0.0002	0.00182	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—liver cancer	0.0002	0.00182	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—liver cancer	0.000195	0.00177	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—liver cancer	0.000186	0.00169	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—liver cancer	0.000181	0.00164	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—liver cancer	0.00018	0.00163	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—liver cancer	0.000173	0.00157	CcSEcCtD
Lidocaine—Rash—Epirubicin—liver cancer	0.000172	0.00156	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—liver cancer	0.000171	0.00156	CcSEcCtD
Lidocaine—Headache—Epirubicin—liver cancer	0.00017	0.00155	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—liver cancer	0.000167	0.00151	CcSEcCtD
Lidocaine—Nausea—Epirubicin—liver cancer	0.000162	0.00147	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—liver cancer	0.00016	0.00145	CcSEcCtD
Lidocaine—Rash—Doxorubicin—liver cancer	0.000159	0.00144	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—liver cancer	0.000159	0.00144	CcSEcCtD
Lidocaine—Headache—Doxorubicin—liver cancer	0.000158	0.00143	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—liver cancer	0.00015	0.00136	CcSEcCtD
Lidocaine—EGFR—Signaling Pathways—TERT—liver cancer	1.47e-05	5.87e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MTOR—liver cancer	1.47e-05	5.86e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CB—liver cancer	1.47e-05	5.86e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARA—liver cancer	1.47e-05	5.86e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—HMOX1—liver cancer	1.47e-05	5.85e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PSMA4—liver cancer	1.45e-05	5.8e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PSMD10—liver cancer	1.45e-05	5.8e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTP1—liver cancer	1.45e-05	5.8e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—HMOX1—liver cancer	1.43e-05	5.72e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYCS—liver cancer	1.43e-05	5.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—liver cancer	1.42e-05	5.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—AKT1—liver cancer	1.42e-05	5.68e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GOT2—liver cancer	1.41e-05	5.64e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GGT1—liver cancer	1.4e-05	5.59e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GOT1—liver cancer	1.4e-05	5.59e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—RAF1—liver cancer	1.39e-05	5.54e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.39e-05	5.53e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.38e-05	5.51e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1B—liver cancer	1.38e-05	5.5e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CG—liver cancer	1.37e-05	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PSMD10—liver cancer	1.37e-05	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PSMA4—liver cancer	1.37e-05	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTM1—liver cancer	1.37e-05	5.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—liver cancer	1.37e-05	5.45e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.36e-05	5.44e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—liver cancer	1.36e-05	5.43e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PSMD10—liver cancer	1.36e-05	5.42e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PSMA4—liver cancer	1.36e-05	5.42e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MTOR—liver cancer	1.36e-05	5.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CB—liver cancer	1.36e-05	5.41e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTA4—liver cancer	1.35e-05	5.4e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—liver cancer	1.35e-05	5.38e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KDR—liver cancer	1.35e-05	5.37e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.34e-05	5.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK14—liver cancer	1.34e-05	5.33e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTM1—liver cancer	1.34e-05	5.33e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GOT2—liver cancer	1.33e-05	5.32e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP2E1—liver cancer	1.33e-05	5.31e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—liver cancer	1.32e-05	5.28e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GOT2—liver cancer	1.32e-05	5.27e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTA2—liver cancer	1.32e-05	5.26e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—JUN—liver cancer	1.31e-05	5.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ESR1—liver cancer	1.31e-05	5.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CTNNB1—liver cancer	1.3e-05	5.2e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HPGDS—liver cancer	1.3e-05	5.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—F2—liver cancer	1.3e-05	5.17e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP1A1—liver cancer	1.3e-05	5.17e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.3e-05	5.17e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1B—liver cancer	1.27e-05	5.08e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1A—liver cancer	1.27e-05	5.08e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTA1—liver cancer	1.27e-05	5.07e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP1A1—liver cancer	1.27e-05	5.05e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTP1—liver cancer	1.26e-05	5.02e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CG—liver cancer	1.26e-05	5.02e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NAT2—liver cancer	1.26e-05	5.02e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—AKT1—liver cancer	1.26e-05	5.01e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.25e-05	5e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP2E1—liver cancer	1.25e-05	5e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYCS—liver cancer	1.24e-05	4.96e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP2E1—liver cancer	1.24e-05	4.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MAPK8—liver cancer	1.24e-05	4.96e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HMOX1—liver cancer	1.24e-05	4.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APC—liver cancer	1.24e-05	4.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CG—liver cancer	1.24e-05	4.95e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GOT1—liver cancer	1.22e-05	4.87e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GGT1—liver cancer	1.22e-05	4.87e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—liver cancer	1.21e-05	4.84e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—MTHFR—liver cancer	1.21e-05	4.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—AKT1—liver cancer	1.21e-05	4.81e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CD—liver cancer	1.21e-05	4.81e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALDOB—liver cancer	1.21e-05	4.81e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.2e-05	4.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CTNNB1—liver cancer	1.2e-05	4.8e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ALB—liver cancer	1.19e-05	4.75e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARA—liver cancer	1.19e-05	4.73e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—MTHFR—liver cancer	1.18e-05	4.71e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.18e-05	4.71e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1A—liver cancer	1.18e-05	4.69e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYCS—liver cancer	1.17e-05	4.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—liver cancer	1.17e-05	4.65e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.16e-05	4.64e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYCS—liver cancer	1.16e-05	4.64e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PSMA4—liver cancer	1.16e-05	4.63e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PSMD10—liver cancer	1.16e-05	4.63e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARA—liver cancer	1.16e-05	4.62e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTM1—liver cancer	1.16e-05	4.62e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GGT1—liver cancer	1.15e-05	4.59e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GOT1—liver cancer	1.15e-05	4.59e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CRABP1—liver cancer	1.15e-05	4.59e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GGT1—liver cancer	1.14e-05	4.55e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GOT1—liver cancer	1.14e-05	4.55e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—liver cancer	1.14e-05	4.53e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GOT2—liver cancer	1.13e-05	4.51e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CD—liver cancer	1.11e-05	4.41e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTP1—liver cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP1A1—liver cancer	1.1e-05	4.38e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ALB—liver cancer	1.09e-05	4.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CD—liver cancer	1.09e-05	4.35e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HMOX1—liver cancer	1.08e-05	4.32e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SERPINE1—liver cancer	1.08e-05	4.3e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—liver cancer	1.07e-05	4.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP2E1—liver cancer	1.06e-05	4.24e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CB—liver cancer	1.05e-05	4.19e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—liver cancer	1.05e-05	4.18e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTP1—liver cancer	1.03e-05	4.12e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.03e-05	4.1e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTP1—liver cancer	1.02e-05	4.09e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—MTHFR—liver cancer	1.02e-05	4.08e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HMOX1—liver cancer	1.02e-05	4.07e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CG—liver cancer	1.02e-05	4.05e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HMOX1—liver cancer	1.01e-05	4.03e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTM1—liver cancer	1.01e-05	4.02e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HPGDS—liver cancer	1.01e-05	4.01e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARA—liver cancer	1e-05	4e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYCS—liver cancer	9.94e-06	3.96e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CG—liver cancer	9.92e-06	3.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—liver cancer	9.81e-06	3.91e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—liver cancer	9.8e-06	3.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—liver cancer	9.75e-06	3.89e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GGT1—liver cancer	9.75e-06	3.89e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GOT1—liver cancer	9.75e-06	3.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—liver cancer	9.75e-06	3.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RAF1—liver cancer	9.73e-06	3.88e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—TGFB1—liver cancer	9.72e-06	3.88e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—liver cancer	9.64e-06	3.85e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CB—liver cancer	9.64e-06	3.84e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—liver cancer	9.58e-06	3.82e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP1A1—liver cancer	9.56e-06	3.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CB—liver cancer	9.5e-06	3.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MTOR—liver cancer	9.5e-06	3.79e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTM1—liver cancer	9.5e-06	3.79e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTM1—liver cancer	9.42e-06	3.76e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—liver cancer	9.07e-06	3.62e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	9.01e-06	3.59e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP1A1—liver cancer	9.01e-06	3.59e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—liver cancer	9e-06	3.59e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PSMD10—liver cancer	8.96e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PSMA4—liver cancer	8.96e-06	3.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—liver cancer	8.96e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP1A1—liver cancer	8.93e-06	3.56e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CD—liver cancer	8.92e-06	3.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1B—liver cancer	8.92e-06	3.56e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—MTHFR—liver cancer	8.91e-06	3.55e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ALB—liver cancer	8.81e-06	3.51e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTP1—liver cancer	8.76e-06	3.49e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARA—liver cancer	8.74e-06	3.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CASP3—liver cancer	8.74e-06	3.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—liver cancer	8.73e-06	3.48e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CD—liver cancer	8.72e-06	3.48e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GOT2—liver cancer	8.72e-06	3.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—liver cancer	8.68e-06	3.46e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HMOX1—liver cancer	8.64e-06	3.45e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ALB—liver cancer	8.61e-06	3.43e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CG—liver cancer	8.59e-06	3.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—liver cancer	8.51e-06	3.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—JUN—liver cancer	8.49e-06	3.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CTNNB1—liver cancer	8.43e-06	3.36e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—MTHFR—liver cancer	8.4e-06	3.35e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—MTHFR—liver cancer	8.32e-06	3.32e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—liver cancer	8.29e-06	3.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—liver cancer	8.29e-06	3.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—liver cancer	8.27e-06	3.3e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—liver cancer	8.26e-06	3.29e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARA—liver cancer	8.24e-06	3.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1A—liver cancer	8.23e-06	3.28e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP2E1—liver cancer	8.2e-06	3.27e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARA—liver cancer	8.17e-06	3.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTM1—liver cancer	8.05e-06	3.21e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MAPK8—liver cancer	8.03e-06	3.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—AKT1—liver cancer	8.01e-06	3.2e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—liver cancer	7.93e-06	3.16e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—AKT1—liver cancer	7.88e-06	3.14e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CB—liver cancer	7.78e-06	3.1e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYCS—liver cancer	7.67e-06	3.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—liver cancer	7.65e-06	3.05e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP1A1—liver cancer	7.63e-06	3.04e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CB—liver cancer	7.6e-06	3.03e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CD—liver cancer	7.55e-06	3.01e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GGT1—liver cancer	7.53e-06	3e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GOT1—liver cancer	7.53e-06	3e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CG—liver cancer	7.49e-06	2.99e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ALB—liver cancer	7.46e-06	2.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—liver cancer	7.42e-06	2.96e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—liver cancer	7.34e-06	2.93e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.34e-06	2.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—liver cancer	7.33e-06	2.92e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—AKT1—liver cancer	7.32e-06	2.92e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—liver cancer	7.23e-06	2.88e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—MTHFR—liver cancer	7.11e-06	2.84e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CG—liver cancer	7.05e-06	2.81e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CG—liver cancer	6.99e-06	2.79e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARA—liver cancer	6.98e-06	2.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—liver cancer	6.82e-06	2.72e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—liver cancer	6.81e-06	2.72e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFB1—liver cancer	6.81e-06	2.72e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTP1—liver cancer	6.76e-06	2.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—AKT1—liver cancer	6.76e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—liver cancer	6.75e-06	2.69e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HMOX1—liver cancer	6.67e-06	2.66e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CB—liver cancer	6.58e-06	2.63e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CD—liver cancer	6.58e-06	2.62e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALB—liver cancer	6.5e-06	2.59e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—liver cancer	6.41e-06	2.56e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—liver cancer	6.31e-06	2.51e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.27e-06	2.5e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTM1—liver cancer	6.21e-06	2.48e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CD—liver cancer	6.2e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CD—liver cancer	6.15e-06	2.45e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALB—liver cancer	6.12e-06	2.44e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALB—liver cancer	6.07e-06	2.42e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CG—liver cancer	5.98e-06	2.38e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP1A1—liver cancer	5.89e-06	2.35e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—liver cancer	5.88e-06	2.34e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—liver cancer	5.79e-06	2.31e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—liver cancer	5.77e-06	2.3e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CB—liver cancer	5.74e-06	2.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—liver cancer	5.6e-06	2.24e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—MTHFR—liver cancer	5.49e-06	2.19e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CB—liver cancer	5.41e-06	2.16e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARA—liver cancer	5.39e-06	2.15e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—liver cancer	5.36e-06	2.14e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CB—liver cancer	5.36e-06	2.14e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CD—liver cancer	5.25e-06	2.1e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—AKT1—liver cancer	5.24e-06	2.09e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALB—liver cancer	5.19e-06	2.07e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—liver cancer	5.13e-06	2.05e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—AKT1—liver cancer	4.8e-06	1.91e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—liver cancer	4.74e-06	1.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—AKT1—liver cancer	4.73e-06	1.89e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—liver cancer	4.63e-06	1.85e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CG—liver cancer	4.61e-06	1.84e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CB—liver cancer	4.58e-06	1.83e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—liver cancer	4.45e-06	1.78e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CD—liver cancer	4.05e-06	1.62e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—liver cancer	4.01e-06	1.6e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALB—liver cancer	4e-06	1.6e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—AKT1—liver cancer	3.87e-06	1.54e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—AKT1—liver cancer	3.79e-06	1.51e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CB—liver cancer	3.53e-06	1.41e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—liver cancer	3.5e-06	1.39e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—liver cancer	3.3e-06	1.31e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—AKT1—liver cancer	3.28e-06	1.31e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—liver cancer	3.27e-06	1.3e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—AKT1—liver cancer	2.86e-06	1.14e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—liver cancer	2.79e-06	1.11e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—AKT1—liver cancer	2.69e-06	1.07e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—AKT1—liver cancer	2.67e-06	1.06e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—AKT1—liver cancer	2.28e-06	9.1e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—liver cancer	2.15e-06	8.59e-06	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—AKT1—liver cancer	1.76e-06	7.02e-06	CbGpPWpGaD
